Phio Pharmaceuticals to Present Clinical Study Results of PH-762 in American Academy of Dermatology's Late-Breaking Research Session

Phio Pharmaceuticals will present clinical study results for its lead product candidate, PH-762, in the American Academy of Dermatology's Late-Breaking Research Session on March 28, 2026. The presentation will highlight the safety and tolerability of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The study showed promising results, with notable pathologic response and modest mean reductions in tumor burden following treatment.